These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 20445836

  • 1. Personality disorders in ADHD Part 2: The effect of symptoms of personality disorder on response to treatment with OROS methylphenidate in adults with ADHD.
    Robison RJ, Reimherr FW, Gale PD, Marchant BK, Williams ED, Soni P, Halls C, Strong RE.
    Ann Clin Psychiatry; 2010 May; 22(2):94-102. PubMed ID: 20445836
    [Abstract] [Full Text] [Related]

  • 2. Personality disorder in ADHD Part 1: Assessment of personality disorder in adult ADHD using data from a clinical trial of OROS methylphenidate.
    Williams ED, Reimherr FW, Marchant BK, Strong RE, Halls C, Soni P, Gale PD, Robison RJ.
    Ann Clin Psychiatry; 2010 May; 22(2):84-93. PubMed ID: 20445835
    [Abstract] [Full Text] [Related]

  • 3. Personality disorders in ADHD Part 3: Personality disorder, social adjustment, and their relation to dimensions of adult ADHD.
    Reimherr FW, Marchant BK, Williams ED, Strong RE, Halls C, Soni P.
    Ann Clin Psychiatry; 2010 May; 22(2):103-12. PubMed ID: 20445837
    [Abstract] [Full Text] [Related]

  • 4. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T.
    Biol Psychiatry; 2006 May 01; 59(9):829-35. PubMed ID: 16373066
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.
    J Clin Psychopharmacol; 2009 Jun 01; 29(3):239-47. PubMed ID: 19440077
    [Abstract] [Full Text] [Related]

  • 6. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A, Richard C, Prinzo R, Binder C.
    Curr Med Res Opin; 2006 Dec 01; 22(12):2557-66. PubMed ID: 17166338
    [Abstract] [Full Text] [Related]

  • 7. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.
    Rösler M, Retz W, Fischer R, Ose C, Alm B, Deckert J, Philipsen A, Herpertz S, Ammer R.
    World J Biol Psychiatry; 2010 Aug 01; 11(5):709-18. PubMed ID: 20353312
    [Abstract] [Full Text] [Related]

  • 8. OROS methylphenidate in the treatment of adults with ADHD: a 6-month, open-label, follow-up study.
    Marchant BK, Reimherr FW, Halls C, Williams ED, Strong RE.
    Ann Clin Psychiatry; 2010 Aug 01; 22(3):196-204. PubMed ID: 20680193
    [Abstract] [Full Text] [Related]

  • 9. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
    Ramos-Quiroga JA, Corominas M, Castells X, Bosch R, Casas M.
    Expert Rev Neurother; 2009 Aug 01; 9(8):1121-31. PubMed ID: 19673602
    [Abstract] [Full Text] [Related]

  • 10. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H.
    Psychiatry Clin Neurosci; 2009 Apr 01; 63(2):167-75. PubMed ID: 19335386
    [Abstract] [Full Text] [Related]

  • 11. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo.
    Levin FR, Evans SM, Brooks DJ, Garawi F.
    Drug Alcohol Depend; 2007 Feb 23; 87(1):20-9. PubMed ID: 16930863
    [Abstract] [Full Text] [Related]

  • 12. Are stimulants effective in the treatment of executive function deficits? Results from a randomized double blind study of OROS-methylphenidate in adults with ADHD.
    Biederman J, Mick E, Fried R, Wilner N, Spencer TJ, Faraone SV.
    Eur Neuropsychopharmacol; 2011 Jul 23; 21(7):508-15. PubMed ID: 21303732
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
    Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L, Adult ADHD Research Group.
    Biol Psychiatry; 2007 Jun 15; 61(12):1380-7. PubMed ID: 17137560
    [Abstract] [Full Text] [Related]

  • 14. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
    Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE.
    Can J Clin Pharmacol; 2006 Jun 15; 13(1):e50-62. PubMed ID: 16456216
    [Abstract] [Full Text] [Related]

  • 15. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.
    Buitelaar JK, Sobanski E, Stieglitz RD, Dejonckheere J, Waechter S, Schäuble B.
    J Clin Psychiatry; 2012 Aug 15; 73(8):1097-102. PubMed ID: 22780962
    [Abstract] [Full Text] [Related]

  • 16. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
    Kordon A, Stollhoff K, Niederkirchner K, Mattejat F, Rettig K, Schäuble B.
    Postgrad Med; 2011 Sep 15; 123(5):27-38. PubMed ID: 21904084
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb 15; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 18. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder.
    Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, Mick E, Aleardi M, Herzig K, Faraone S.
    Biol Psychiatry; 2005 Mar 01; 57(5):456-63. PubMed ID: 15737659
    [Abstract] [Full Text] [Related]

  • 19. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
    Huang YS, Guilleminault C, Li HY, Yang CM, Wu YY, Chen NH.
    Sleep Med; 2007 Jan 01; 8(1):18-30. PubMed ID: 17157069
    [Abstract] [Full Text] [Related]

  • 20. Effects of MPH-OROS on the organizational, time management, and planning behaviors of children with ADHD.
    Abikoff H, Nissley-Tsiopinis J, Gallagher R, Zambenedetti M, Seyffert M, Boorady R, McCarthy J.
    J Am Acad Child Adolesc Psychiatry; 2009 Feb 01; 48(2):166-75. PubMed ID: 19127171
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.